Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-07-05T16:06:38.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Varenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression

Published online by Cambridge University Press:  07 November 2014

Andres J. Pumariega ,
Robert Nelson  and
Larry Rotenberg
Get access Rights & Permissions [Opens in a new window]

Abstract

Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.

Type
Case Report
Information
CNS Spectrums , Volume 13 , Issue 6 , June 2008 , pp. 511 - 514
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ezzi, M, Lopez, A. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–852.Google Scholar
2.Gonzales, D, Rennard, S, Nides, M, et al.Varenicline, an α4 β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.Google Scholar
3.Jorenby, DE, Hays, JR, Rigotti, NA, et al.Efficacy of varenicline, an α4 β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.Google Scholar
4.Tonstad, S, Tonnesen, P, Hajek, Pet al.Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.Google Scholar
6.Coe, J, Brooks, P, Vertelino, M, et al.Varenicline: an α4 β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477.Google Scholar
7. Food and Drug Administration. FDA Med Watch Alert, Varenicline (marketed as Chantix): Information, February 1, 2008, and November 20, 2007. Available at www.fda.gov/cder/drug/infopage/varenicline/default.htm. Accessed April 20, 2008.Google Scholar
7.Kohen, I, Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:1269–1270.Google Scholar
8.Freedman, R. Exacerbation of schizophrenia by varenicline [letter]. Am J Psychiatry. 2007;164:1269.Google Scholar
9.Bupropion, SR [package insert]. Corona, Calif: Watson Pharmaceuticals; 2006.Google Scholar
10.Goldberg, JF, Perlis, RH, Ghaemi, SN, et al.Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry. 2007;164:1348–1355.Google Scholar